Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer

(MedPage Today) -- SAN ANTONIO -- The addition of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) boosted progression-free survival (PFS) in patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news